Hims & Hers Health, Inc. Class A Common Stock (HIMS)
16.62
-0.43 (-2.52%)
NYSE · Last Trade: Nov 19th, 10:10 AM EST
Detailed Quote
| Previous Close | 17.05 |
|---|---|
| Open | 17.20 |
| Bid | 16.60 |
| Ask | 16.63 |
| Day's Range | 16.61 - 17.28 |
| 52 Week Range | 13.74 - 40.99 |
| Volume | 2,209,488 |
| Market Cap | 3.19B |
| PE Ratio (TTM) | -20.02 |
| EPS (TTM) | -0.8 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 14,670,520 |
Chart
About Hims & Hers Health, Inc. Class A Common Stock (HIMS)
Hims & Hers Health Inc is a telehealth company that focuses on providing accessible and affordable healthcare solutions for a variety of needs, particularly focusing on personal wellness and self-care. The company offers a range of products and services, including prescription medications for conditions such as hair loss, erectile dysfunction, and skincare, as well as wellness supplements and telemedicine consultations. By leveraging technology, Hims & Hers aims to simplify the healthcare experience, making it more convenient for consumers to receive treatment and advice from licensed professionals without the barriers typically associated with traditional healthcare delivery. Read More
News & Press Releases
GLP-1 Treatments, Anticancer Research, and Emerging Therapeutic Technologies Are Driving the Next Chapter of Pharmaceutical Innovation
By FN Media · Via GlobeNewswire · November 19, 2026
EQNX::TICKER_START (OTCQB:PNGAF),(CSE:BPC),(NYSE:LLY),(NYSE:HIMS),(TSXV:PAIN),(CSE:VLAB) EQNX::TICKER_END
Via FinancialNewsMedia · November 19, 2026
Hims & Hers (NYSE: HIMS) today announced the launch of Peptides+, a new specialty built around clinically-guided protocols designed to target health at the cellular level. After a clinical visit with a licensed provider, eligible customers may be prescribed a personalized treatment plan including up to five treatments at launch: Sermorelin, NAD+, Glutathione, Vitamin B12, and L-Carnitine, depending on their needs as determined by their provider. Access to BPC-157 and TB-500 will follow, consistent with regulatory standards.
By Hims & Hers · Via Business Wire · November 18, 2026
The company generated strong growth last quarter, but its bottom line didn't look nearly as impressive.
Via The Motley Fool · November 16, 2026
Revenue is increasing, but so are its operating expenses.
Via The Motley Fool · November 14, 2026
Hims & Hers stock crashed after issuing weak guidance.
Via The Motley Fool · November 13, 2026
Hims & Hers stock sank after a Q3 earnings and revenue miss, lower EBITDA guidance, subscriber declines, and an expanding FTC lawsuit over privacy and billing practices.
Via MarketBeat · November 12, 2026
Healthcare Innovation and Technology Adoption Are Reshaping How Millions of Patients Access Medical Services
By FN Media · Via GlobeNewswire · November 11, 2026
EQNX::TICKER_START (OTCQB:AIRDF),(CSE:AIDR),(NYSE:TDOC),(NYSE:AMWL),(NYSE:HIMS),(NYSE:DOCS) EQNX::TICKER_END
Via FinancialNewsMedia · November 11, 2026
What happened? Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 18.5% in the afternoon session after the company reported its financial resul...
Via StockStory · November 10, 2026
Management is betting that a lighter marketing push now sets Hims & Hers up for the January weight-loss surge, but it's unclear whether lost subscribers will return.
Via The Motley Fool · November 10, 2026
Stock Market Today: Nvidia Board Opens Probe Into Jensen Huang as Wall Street Licks Its AI Woundschartmill.com
Via Chartmill · November 10, 2026
International expansion offset a U.S. subscriber slowdown in the quarter.
Via The Motley Fool · November 10, 2026
Telehealth company Hims & Hers Health (NYSE:HIMS) met Wall Street’s revenue expectations in Q3 2026, with sales up 48.6% year on year to $890.4 million. On t...
Via StockStory · November 10, 2026
Hims & Hers Health (NYSE:HIMS) reported third-quarter revenue growth of 49% but lost 100,000 subscribers from the prior quarter, as the digital health company held back U.S. weight-loss marketing and consolidated brands in international markets.
Revenue rose to $890 million, while subscribers i
Via MarketBeat · November 10, 2026
Telehealth company Hims & Hers Health (NYSE:HIMS) met Wall Street’s revenue expectations in Q3 2026, with revenue up 48.6% year on year to $890.4 million. On...
Via StockStory · November 9, 2026
Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading global health and wellness platform, announced the appointment of Andrew Huberman, Ph.D., to the company’s Board of Directors.
By Hims & Hers · Via Business Wire · November 9, 2026
Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading global health and wellness platform, today announced financial results for the third quarter ended September 30, 2026.
By Hims & Hers · Via Business Wire · November 9, 2026
Telehealth company Hims & Hers Health (NYSE:HIMS) will be reporting earnings this Monday after market close. Here’s what you need to know. Hims & Hers Health...
Via StockStory · November 7, 2026
Both are disruptors, but one of these growth stocks stands out over the other.
Via The Motley Fool · November 6, 2026
Eli Lilly and Company (NYSE: LLY) and Hims & Hers Health, Inc. (NYSE: HIMS) today announced an agreement to help expand access to Zepbound (tirzepatide) and Foundayo (orforglipron). Through the agreement, eligible patients who receive a prescription from a licensed provider on the Hims & Hers platform will access the same self-pay prices available to any patient without leaving the Hims & Hers platform.
By Hims & Hers · Via Business Wire · November 6, 2026
Via MarketBeat · November 5, 2026
New HHS Direction Creates Potential Opportunities for Peptide Manufacturers, Biotech Companies, and Healthcare Innovators
By FN Media · Via GlobeNewswire · November 5, 2026
EQNX::TICKER_START (OTCQB:PNGAF),(CSE:BPC),(NASDAQ:MBX),(NASDAQ:KLRA),(NASDAQ:ALT),(NYSE:HIMS) EQNX::TICKER_END
Via FinancialNewsMedia · November 5, 2026
Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced four new partners joining Hims & Hers Benefits: Grüns®, Medjet®, Tonal™, and Viome™. The program launched in March with two partners and has grown to include 14, with benefits designed to support subscribers’ whole-body health, including through a GLP-1 weight loss journey.
By Hims & Hers · Via Business Wire · November 5, 2026
